Drug Development

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

Key information is needed for excipients and their potential impact on continuous manufacturing processes.

Syngene's new production platform offers rapid protein synthesis with lower risk.

At BIO 2024 in San Diego, John Dunlop, PhD, chief scientific officer at Aliada Therapeutics, sat down for an interview with Pharmaceutical Technology to discuss the firm’s MODEL platform and its potential impact on therapeutic delivery for brain-related conditions.

CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.

Webinar Date/Time: Wednesday, July 10, 2024 - 11am EDT | 4pm GMT | 5pm CEST

A statistical analysis for determining an expiration date can be applied to replicates or their corresponding averages as suggested in industry guidelines.

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.

Webinar Date/Time: Thu, Jun 27, 2024 11:00 AM EDT

Webinar Date/Time: Thursday, June 20, 2024 - 11am EDT | 4pm GMT | 5pm CEST

Webinar Date/Time: Thu, Jun 20, 2024 11:00 AM EDT

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.

The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Webinar Date/Time: Mon, Jun 24, 2024 11:00 AM EDT

The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.

Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, Regeneron, discussed the utility of AI and how it can benefit R&D work.

Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.

Webinar Date/Time: Wednesday, May 29th 11am EDT | 4pm GMT | 5pm CEST

Webinar Date/Time: Wed, Jun 12, 2024 11:00 AM EDT

Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.